RecruitingPhase 3NCT05086614

Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer

The Efficacy and Safety of Thymosin-alpha 1 Used for Adjuvant Treatment After Radical Resection of High-risk Stage II and Stage III Colorectal Cancer

Sponsor

Fudan University

Enrollment

2,500 participants

Start Date

Apr 1, 2021

Study Type

INTERVENTIONAL

Conditions

Stage III Colorectal Cancer Stage II Colorectal Cancer

Summary

For high-risk stage II and stage III colorectal cancer, even after radical resection and postoperative adjuvant chemo/radiotherapy, 30-40% of patients will still have recurrence and metastasis. Thymosin-alpha 1 is believed to improve immunity and may help promote tumor immunity to reduce the incidence of recurrence and metastasis. This study hopes to verify the effecacy and safety of thymosin-alpha 1 for adjuvant treatment of high-risk stage II and stage III colorectal cancer after radical resection.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This trial tests whether thymosin-alpha 1, an immune-boosting medication, can improve outcomes for people who have had surgery for high-risk colon or rectal cancer. You may be eligible if... - You have had a complete (radical) surgical removal of colorectal cancer - Your cancer was confirmed by pathology as high-risk stage II or stage III - Your overall health status (ECOG) is 0, 1, or 2 - Your liver, kidney, and blood counts are within acceptable ranges You may NOT be eligible if... - You have previously taken any immune-boosting medications - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.